At the time of writing, Evaxion Biotech A/S ADR [EVAX] stock is trading at $6.00, down -0.50%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The EVAX shares have gain 94.17% over the last week, with a monthly amount glided 32.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Evaxion Biotech A/S ADR [NASDAQ: EVAX] stock has seen the most recent analyst activity on April 02, 2024, when Ladenburg Thalmann upgraded its rating to a Buy but kept the price target unchanged to $8 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on February 12, 2024, and set its price target to $14.
For the past year, the stock price of Evaxion Biotech A/S ADR fluctuated between $2.38 and $53.45. Evaxion Biotech A/S ADR [NASDAQ: EVAX] shares were valued at $6.00 at the most recent close of the market.
Analyzing the EVAX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -4.57%, Pretax Profit Margin comes in at -3.69%, and Net Profit Margin reading is -3.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is 57.66 and Total Capital is -0.99.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.08 points at the first support level, and at 4.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.24, and for the 2nd resistance point, it is at 8.49.
Ratios To Look Out For
It is important to note that Evaxion Biotech A/S ADR [NASDAQ:EVAX] has a current ratio of 2.80. In addition, the Quick Ratio stands at 2.80. Considering the valuation of this stock, the price to sales ratio is 2.13, the price to book ratio is 5.18.
